EXPERIENCE OF LONG-TERM USE OF DIENOGEST FOR THE TREATMENT OF ADENOMYOSIS
| Autor: | O B Kalinkina, O R Aravina, Tezikov Yu.V., I S Lipatov |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
030219 obstetrics & reproductive medicine business.industry General Engineering Urology 030209 endocrinology & metabolism medicine.disease Term (time) 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Dienogest chemistry Medicine Adenomyosis business |
| Zdroj: | "Medical & pharmaceutical journal "Pulse". :92-99 |
| ISSN: | 2686-6838 |
| Popis: | Endometriosis refers to a chronic, often recurrent disease that requires the appointment of a long-term management plan and the patient with the appointment of therapy that effectively affects the clinic of this disease, at the same time having good tolerability, ensuring the patient's adherence to this method of treatment. This dictates the need for careful selection of a drug that meets such requirements. Moreover, studies of drug therapy for endometriosis should also be prolonged. In this case, they allow you to qualitatively assess the effectiveness of a particular type of treatment in the context of routine clinical practice. The main clinical manifestations of endometriosis of the uterine body-adenomyosis are pain syndrome, manifested by various types of pain (dysmenorrhea, dyspareunia, dyschesia, chronic pelvic pain) and the presence of abundant uterine bleeding. The presented clinical case demonstrates the effectiveness of long-term (for 36 months) use of dienogest at a dosage of 2 mg per day (the drug Vizanna) in a continuous mode in the treatment of a patient with adenomyosis. By the 4th month of therapy, the pain syndrome, manifested by dysmenorrhea and dyspareunia, which is the leading clinical manifestation of this pathology in the patient, was completely stopped. The proposed type of therapy has also demonstrated its effectiveness in relation to another clinical manifestation of the disease - heavy uterine bleeding. By the 6th month of therapy, the patient had developed persistent amenorrhea. Good tolerability and the absence of side effects, along with a pronounced clinical effect, led to a high adherence of the patient to this type of drug therapy and allowed her to continue it in the future with dynamic monitoring. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|